Taro Pharmaceutical Industries (NYSE:TARO) had its target price reduced by HC Wainwright from $115.00 to $105.00 in a research note published on Monday, The Fly reports. HC Wainwright currently has a buy rating on the stock.
Other analysts have also recently issued research reports about the company. Zacks Investment Research cut Taro Pharmaceutical Industries from a hold rating to a strong sell rating in a research report on Thursday, June 13th. TheStreet cut Taro Pharmaceutical Industries from a b- rating to a c rating in a report on Thursday, May 23rd. Finally, ValuEngine cut Taro Pharmaceutical Industries from a hold rating to a sell rating in a report on Thursday, May 23rd.
Taro Pharmaceutical Industries stock opened at $80.52 on Monday. The stock has a market cap of $3.21 billion, a PE ratio of 11.14 and a beta of 0.48. The stock has a 50-day moving average price of $83.07 and a 200 day moving average price of $96.42. Taro Pharmaceutical Industries has a 52 week low of $76.93 and a 52 week high of $110.30.
Institutional investors and hedge funds have recently bought and sold shares of the business. Norges Bank purchased a new stake in shares of Taro Pharmaceutical Industries during the 4th quarter worth about $20,825,000. Renaissance Technologies LLC grew its holdings in shares of Taro Pharmaceutical Industries by 29.6% during the 2nd quarter. Renaissance Technologies LLC now owns 552,964 shares of the company’s stock worth $47,234,000 after purchasing an additional 126,164 shares during the period. Acadian Asset Management LLC grew its holdings in shares of Taro Pharmaceutical Industries by 16.8% during the 1st quarter. Acadian Asset Management LLC now owns 360,414 shares of the company’s stock worth $38,954,000 after purchasing an additional 51,826 shares during the period. AJO LP grew its holdings in shares of Taro Pharmaceutical Industries by 23.6% during the 1st quarter. AJO LP now owns 216,550 shares of the company’s stock worth $23,407,000 after purchasing an additional 41,416 shares during the period. Finally, First Manhattan Co. purchased a new stake in shares of Taro Pharmaceutical Industries during the 1st quarter worth about $3,810,000. Institutional investors own 9.79% of the company’s stock.
About Taro Pharmaceutical Industries
Taro Pharmaceutical Industries Ltd., a science-based pharmaceutical company, engages in the development, manufacture, and marketing of pharmaceutical products in the United States, Canada, Israel, and internationally. It offers prescription and over-the-counter pharmaceutical products focusing on primary areas, including topical creams and ointments, liquids, capsules, and tablets in the dermatological and topical, cardiovascular, neuropsychiatric, and anti-inflammatory therapeutic categories.
Further Reading: How does inflation affect different investments?
Receive News & Ratings for Taro Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Taro Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.